Moderna, Inc. (MRNA) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$235.49

From 52W high+0.00%

Volume14.67M

Market cap$103.15B

P/E (TTM)—

P/S (TTM)46.3x

Div yield—

Key dataNov 4, 2026

Open

$235.49

From 52W high

+0.00%

Volume

14.67M

Market cap

$103.15B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−35.1x

P/E (TTM)

—

RSI (14)

65.6

MomentumView details →

1D Return

+13.11%

YTD Return

+739.86%

SummaryUpdated Jun 1, 2026

Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company founded in 2010 and headquartered in Cambridge, Massachusetts. The company went public in December 2018 and gained global prominence during the COVID-19 pandemic as one of the first companies to develop and commercialize an mRNA-based vaccine. Originally founded as Moderna Therapeutics, the company changed its name to Moderna, Inc. in August 2018. Today, Moderna has evolved from a single-product COVID vaccine company into a multi-product biotechnology firm with an expanding pipeline of mRNA-based therapeutics and vaccines across multiple disease areas.

Ask drillr about Moderna, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−35.1x

EV/Sales

44.6x

P/S (TTM)

46.3x

P/B (TTM)

15.3x

ProfitabilityView details →

Gross Margin

−12.57%

Net Margin

−141.43%

EBITDA Margin

−126.97%

ROE (TTM)

−46.61%

ROA (TTM)

−28.75%

Asset Turnover

0.20x

GrowthView details →

Revenue YoY

−27.19%

EPS YoY

−6.03%

FCF YoY

+65.06%

Revenue CAGR 3Y

−53.13%

EPS CAGR 3Y

+21.68%

EBITDA YoY

−3.89%

MomentumView details →

1D Return

+13.11%

YTD Return

+739.86%

1Y Return

+951.25%

RSI (14)

65.6

vs 50D SMA

+32.05%

vs 200D SMA

+176.91%

Capital & dividendView details →

Debt/Equity

0.19x

Current Ratio

2.29x

Quick Ratio

2.18x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.97

EPS Surprise

2.96%

Beats (12Q)

11/12

Next Q EPS Est

−$1.73

Avg Surprise (4Q)

38.86%

Rev Surprise

41.07%

Financials snapshotView financials →

Revenue (TTM)

2.23B

Net Income (TTM)

−3.15B

Op. CF (TTM)

−1.05B

Next earningsNov 6, 2026 →

Latest newsMore news →

Moderna, Inc. shares fell sharply, potentially ending a rally driven by optimism about its cancer vaccine.9d ago

Moderna, Inc. and Merck released detailed results from a late-stage trial showing that adding personalized intismeran to Keytruda reduced the two-year risk of melanoma recurrence by 42% compared with Keytruda alone.10d ago

Similar companies

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.06990.HK Regeneron Pharmaceuticals, Inc.REGN Genexine, Inc.095700.KQ iNtRON Biotechnology, Inc.048530.KQ Sino Biopharmaceutical Limited01177.HK Vaxcell-Bio Therapeutics Co., Ltd.323990.KQ Find similar companies →

Latest newsMore news →

Moderna, Inc. shares fell sharply, potentially ending a rally driven by optimism about its cancer vaccine.9d ago Moderna, Inc. and Merck released detailed results from a late-stage trial showing that adding personalized intismeran to Keytruda reduced the two-year risk of melanoma recurrence by 42% compared with Keytruda alone.10d ago Moderna, Inc. shares fell sharply during the past week.12d ago